TORONTO and HOUSTON, Oct. 23, 2025 (GLOBE NEWSWIRE) — Medicenna Therapeutics Corp. (“Medicenna” or the “Company”) (TSX: MDNA, OTCQX: MDNAF), a clinical-stage immunotherapy company developing superkines targeting cancer and autoimmune diseases, today announced that updated MDNA11 clinical data will be presented to the European Society Congress of Immuno-Oncology Medical Oncology (ESMO) 2025 will take place 10–12 December 2025 in London, UK.
Updated clinical data from the Phase 1/2 ABILITY-1 study evaluating MDNA11, a new best-in-class IL-2 therapy, as monotherapy and in combination with pembrolizumab, will be presented by Dr. Andre Mansigno, the study's principal investigator.
Details of the presentations are as follows:
Heading: ABILITY-1 Phase 1/2 MDNA11, a Next-Generation IL-2 Agonist, Alone or in Combination with Pembrolizumab for Advanced Solid Tumors: An Interim Analysis
Leading: Dr. André Mansigno, MD, Associate Professor, Faculty of Medicine, University of Lisbon
Date: December 10, 2025
After the conclusion of the ESMO Immuno-Oncology 2025 Congress, a copy of the presentation will be available on the website “Events and presentationsMedicenna website page.
About Medicenna Therapeutics
Medicenna is a clinical-stage immunotherapy company developing new highly selective versions of the superkines IL-2, IL-4 and IL-13, as well as first-in-class Empowered Superkines. Medicenna's long-acting superkine IL-2, MDNA11, is a next-generation IL-2 with superior affinity for CD122 (IL-2 receptor beta) and lack of binding to CD25 (IL-2 receptor alpha), thereby preferentially stimulating cancer-killing effector T cells and NK cells. Medicenna's first-in-class targeted PD-1 x IL-2 bispecific, MDNA113, is in development for the treatment of solid tumors and was developed using the company's proprietary BiSKITs™ (Bifunctional Immunotherapy SuperKine) and T-MASK™ (Targeted Metalloprotease Activated SuperKine). Medicenna IL-4 Empowered Superkine, bisaxofusp (formerly MDNA55), was studied in 5 clinical studies involving more than 130 patients, including a phase 2b study in recurrent GBM, the most common and consistently fatal form of brain cancer. Bisaxofusp has received FastTrack and Orphan Drug designations from the FDA and FDA/EMA, respectively.
For more information visit www.medicenna.comand subscribe to us X And LinkedIn.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of applicable securities laws. Forward-looking statements include, but are not limited to, express or implied statements regarding the Company's future performance, estimates, plans, strategic ambitions, partnerships and opportunities, goals, expectations, opinions, forecasts, forecasts, guidance, prospects or other statements that are not historical facts, such as statements regarding the therapeutic potential and safety profile of MDNA11. Drug development and commercialization involves a high degree of risk, and few research and development programs lead to product commercialization. Results from early-stage preclinical or clinical studies may not be representative of complete results or results from later-stage or larger clinical studies and do not guarantee regulatory approval. You should not place undue reliance on these statements or the scientific data presented.
Forward-looking statements are often identified by terms such as “will,” “may,” “should,” “expect,” “anticipate,” “believe,” “seek,” “potential” and similar expressions. and are subject to risks and uncertainties. There can be no assurance that such statements will prove to be accurate, and actual results and future events could differ materially from those anticipated in such statements. Important factors that could cause actual results to differ materially from the Company's expectations include the risks detailed in the Company's most recent annual information form and other documents filed by the Company from time to time with the relevant securities regulatory authorities in Canada.
The reader is cautioned that the assumptions used in preparing any forward-looking information may prove to be incorrect. Events or circumstances could cause actual results to differ materially from those projected as a result of numerous known and unknown risks, uncertainties and other factors, many of which are beyond the Company's control. The reader is cautioned not to place undue reliance on any forward-looking information. Such information, although believed to be reasonable by management, may prove to be incorrect and actual results may differ materially from those anticipated. Forward-looking statements contained in this press release are expressly qualified by this cautionary statement. The forward-looking statements contained in this press release are made as of the date hereof and, except as required by law, we do not intend, and do not undertake any obligation, to publicly update or revise any forward-looking statements included herein.
This press release contains hyperlinks to information that is not deemed to be incorporated by reference in this new release.
Investor/Media Contact:
Shushu Feng
Investor Relations, Medicenna Therapeutics
(416) 964-5442
[email protected]
:quality(85):upscale()/2025/01/24/681/n/1922153/3e005d8b6793b0019afcd1.50804215_.jpg?w=150&resize=150,150&ssl=1 "What Is Fanxiety Face? How Watching Sports Affects Your Skin")
